Aerin Medical Inc.

Aerin Medical Inc. manufactures minimally invasive radiofrequency (RF) treatment systems for chronic nasal conditions. The company's primary product line consists of two office-based platforms: VivAer Stylus, designed to treat nasal airway obstruction (NAO) by remodeling soft tissue and cartilage in the nasal valve, lateral wall, inferior turbinate, and septal swell body; and RhinAer Stylus, designed to treat chronic rhinitis by disrupting the posterior nasal nerve to relieve runny nose, post-nasal drip, congestion, itching, and sneezing symptoms. Both systems utilize a compact touch-screen console paired with interchangeable stylus applicators that deliver precise, temperature-controlled radiofrequency energy. Treatments are incisionless, performed under local anesthesia, and designed for convenient office or operating room use with minimal patient downtime. The company addresses a large patient population: approximately 20 million NAO sufferers and 90 million rhinitis sufferers (allergic and non-allergic combined) in the United States. Clinical evidence demonstrates durable, long-lasting therapeutic outcomes. As of March 2026, Aerin Medical has treated over 200,000 patients with its VivAer and RhinAer platforms. The devices target ENT specialists and surgical centers seeking non-invasive alternatives to traditional nasal surgery.